Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis

World Journal of Surgical Oncology

Volumn 13, Issue 1, 2015, Pages

  Han, Zhengquan ^a,b   Chen, Zhendong ^a   Zheng, Rongsheng ^b   Cheng, Zenong ^b   Gong, Xiaomeng ^b   Wang, Danna ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b BENGBU MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CD82 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; CD44 PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PROM1 PROTEIN, HUMAN;

ADULT; ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CAPILLARY DENSITY; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR VOLUME; AGED; BREAST TUMOR; FEMALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR INVASION; VASCULARIZATION; YOUNG ADULT;

AC133 ANTIGEN; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD44; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PROGNOSIS; YOUNG ADULT;

EID: 84924117796     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/s12957-015-0486-9     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Kamel M, Shouman S, El-Merzebany M, Kilic G, Veenstra T, Saeed M, et al. Effect of tumour necrosis factor-alpha on estrogen metabolic pathways in breast cancer cells. J Cancer. 2012;3:310-21.
3. Camerini A, Donati S, Viacava P, Siclari O, Puccetti C, Tartarelli G, et al. Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. J Exp Clin Cancer Res. 2011;30:38.
4. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893-907.
5. Radenkovic S, Milosevic Z, Konjevic G, Karadzic K, Rovcanin B, Buta M, et al. Lactate dehydrogenase, catalase, and superoxide dismutase in tumor tissue of breast cancer patients in respect to mammographic findings. Cell Biochem Biophys. 2013;66:287-95.
6. Radenkovic S, Konjevic G, Jurisic V, Karadzic K, Nikitovic M, Gopcevic K. Values of MMP-2 and MMP-9 in tumor tissue of basal-like breast cancer patients. Cell Biochem Biophys. 2014;68:143-52.
7. Stankovic S, Konjevic G, Gopcevic K, Jovic K, Inic M, Jurisic V. Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathol Res Pract. 2010;206:241-7.
8. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65:5506-11.
9. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-11.
10. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
11. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141-6.
12. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12:895-904.
13. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997;90:5013-21.
14. Aomatsu N, Yashiro M, Kashiwagi S, Takashima T, Ishikawa T, Ohsawa M, et al. CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One. 2012;7:e45865.
15. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008;99:1285-9.
16. Wu S, Yu L, Wang D, Zhou L, Cheng Z, Chai D, et al. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC Cancer. 2012;12:535.
17. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46:1271-7.
18. Bánky B, Rásó-Barnett L, Barbai T, Tímár J, Becságh P, Rásó E. Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression. Mol Cancer. 2012;11:83.
19. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci. 2002;39(6):527-79.
20. Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B, et al. Prognostic impact of VEGF, CD31, CD34 and CD105 expression and tumor vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004;57:591-7.
21. Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G, et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol. 2004;57:965-9.
22. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 1995;268:884-6.
23. Malik FA, Sanders AJ, Jiang WG. KAI-1/CD82, the molecule and clinical implication in cancer and cancer metastasis. Histol Histopathol. 2009;24:519-30.
24. Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol. 2004;17:1141-9.
25. Carrasco E, Alvarez PJ, Prados J, Melguizo C, Rama AR, Aránega A, et al. Cancer stem cells and their implication in breast cancer. Eur J Clin Invest. 2014. doi:10.1111/eci.12276.
26. Camerlingo R, Ferraro GA, De Francesco F, Romano M, Nicoletti G, Di Bonito M, et al. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer. Oncol Rep. 2014;31:1127-32.
27. Wang XY, Penalva LO, Yuan H, Linnoila RI, Lu J, Okano H, et al. Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer. 2010;9:221.
28. Martin TA, Jiang WG. Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma. Oncol Rep. 2014;31:262-72.
29. Zhao P, Li Y, Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer. 2010;10:218.
30. Schneider M, Huber J, Hadaschik B, Siegers GM, Fiebig HH, Schüler J. Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer. 2012;12:96.
31. Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ, Molven A. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 2008;8:48.
32. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504-14.
33. Leta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol. 2008;15:638-48.
34. Pode-Shakked N, Metsuyanim S, Rom-Gross E, et al. Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population. J Cell Mol Med. 2009;13:1792-808.
35. Zhang Y, Sun B, Zhao X, Liu Z, Wang X, Yao X, et al. Clinical significances and prognostic value of cancer stem-like cells and vasculogenic mimicry in renal cell carcinoma. J Surg Oncol. 2013;108:414-9.
36. Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int. 2012;62:112-9.
37. Marioni G, D'Alessandro E, Giacomelli L, De Filippis C, Calgaro N, Sari M, et al. Maspin nuclear localization is related to reduced density of tumour-associated micro-vessels in laryngeal carcinoma. Anticancer Res. 2006;26:4927-32.
38. Miranti CK. Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis. Cell Signal. 2009;21:196-211.
39. Malik FA, Sanders AJ, Kayani MA, Jiang WG. Effect of expressional alteration of KAI1 on breast cancer cell growth, adhesion, migration and invasion. Cancer Genomics Proteomics. 2009;64:205-13.
40. Abe M, Sugiura T, Takahashi M, Ishii K, Shimoda M, Shirasuna K. A novel function of CD82/KAI-1 on E-cadherin-mediated homophilic cellular adhesion of cancer cells. Cancer Lett. 2008;266:163-70.
41. Shiwu W, Lan Y, Wenqing S, Lei Z, Yisheng T. Expression and clinical significance of CD82/KAI1 and E-cadherin in non-small cell lung cancer. Arch Iran Med. 2012;15:707-12.
42. Fessler E, Dijkgraaf FE, De Sousa E, Melo F, Medema JP. Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? Cancer Lett. 2013;341:97-104.